Language:

The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers

International journal of molecular sciences, 2020-07, Vol.21 (14), p.5034 [Peer Reviewed Journal]

2020 by the authors. 2020 ;ISSN: 1422-0067 ;ISSN: 1661-6596 ;EISSN: 1422-0067 ;DOI: 10.3390/ijms21145034 ;PMID: 32708748

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers
Author: Kooshkaki, Omid ; Derakhshani, Afshin ; Safarpour, Hossein ; Najafi, Souzan ; Vahedi, Parviz ; Brunetti, Oronzo ; Torabi, Mitra ; Lotfinejad, Parisa ; Paradiso, Angelo Virgilio ; Racanelli, Vito ; Silvestris, Nicola ; Baradaran, Behzad
Subjects: Animals ; Antineoplastic Agents, Immunological - adverse effects ; Antineoplastic Agents, Immunological - therapeutic use ; Female ; Genital Neoplasms, Female - drug therapy ; Genital Neoplasms, Female - immunology ; Genital Neoplasms, Female - pathology ; Genital Neoplasms, Female - therapy ; Genitalia, Female - drug effects ; Genitalia, Female - immunology ; Genitalia, Female - pathology ; gynecologic cancers ; Humans ; immune checkpoint inhibitors ; Immune Checkpoint Inhibitors - adverse effects ; Immune Checkpoint Inhibitors - therapeutic use ; PD-1 inhibitors ; PD-L1 inhibitors ; Review
Is Part Of: International journal of molecular sciences, 2020-07, Vol.21 (14), p.5034
Description: Gynecologic cancers account for approximately 11% of the newly diagnosed cancers in women in the United States and for 18% globally. The presence of tumor-infiltrating lymphocytes (TILs) influences the clinical outcome of cancer patients and immune checkpoint inhibitors (ICIs), including anti programmed cell death protein-1 (anti-PD-1), anti-programmed death-ligand 1 (anti-PD-L1), and anticytotoxic T-lymphocyte antigen 4 (anti-CTLA-4), which have been approved for treating different types of malignancies. Antibodies targeting the PD-1/PD-L1 checkpoint have shown dynamic and durable tumor regressions, suggesting a rebalancing of the host-tumor interaction. There are several the US food and drug administration (FDA)-approved ICIs targeting PD-1, including pembrolizumab and nivolumab, as well as those targeting PD-L1, including avelumab, atezolizumab, and durvalumab for melanoma, renal cell cancer, colorectal cancer, head and neck cancer, cervix cancer, urothelial cancer, and lung cancer. Current pre-clinical and clinical studies assessing PD-1/PD-L1 inhibitors in several gynecologic cancers have reported significant antitumor activity. In this review, we investigate pre-clinical and clinical studies that describe the safety and efficacy of anti-PD-1/PD-L1 antibodies, with a particular focus on ongoing clinical trials, analyzing the oncological outcome and adverse effects of ICIs in gynecologic cancers.
Publisher: Switzerland: MDPI
Language: English
Identifier: ISSN: 1422-0067
ISSN: 1661-6596
EISSN: 1422-0067
DOI: 10.3390/ijms21145034
PMID: 32708748
Source: Open Access: PubMed Central
AUTh Library subscriptions: ProQuest Central
MEDLINE

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers

2020 by the authors. 2020 ;ISSN: 1422-0067 ;ISSN: 1661-6596 ;EISSN: 1422-0067 ;DOI: 10.3390/ijms21145034 ;PMID: 32708748

Searching Remote Databases, Please Wait